ENHERTU (fam-trastuzumab deruxtecan)
HER2+ Breast Cancer (post-neoadjuvant)
Key Facts
Indication
HER2+ Breast Cancer (post-neoadjuvant)
Phase
Phase 3
Status
Priority Review granted
Company
About Daiichi Sankyo
Daiichi Sankyo is a Japanese pharmaceutical giant with over 125 years of medical innovation, operating in 30+ countries and publicly traded on the Tokyo Stock Exchange. The company has pivoted strategically to become a global oncology leader by 2030, leveraging its breakthrough DXd ADC technology platform. With flagship products like ENHERTU (developed with AstraZeneca) showing exceptional results across multiple cancer types, Daiichi Sankyo represents one of the most promising ADC technology platforms in oncology today.
View full company profile